查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1941605

植入式药物输送装置市场规模、份额、趋势及预测（依产品类型、技术、应用、最终用户及地区划分），2026-2034年

Implantable Drug Delivery Devices Market Size, Share, Trends and Forecast by Product Type, Technology, Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

2025年全球植入式药物输送装置市场规模为162亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到280亿美元，2026年至2034年的复合年增长率（CAGR）为6.25%。北美目前占据市场主导地位，预计2025年将占据超过40.7%的市场。人工智慧（AI）智慧感测器、可生物降解材料以及微型化长效植入的日益普及，正在推动市场成长。此外，即时给药演算法和云连接提高了给药精度并减少了用药错误，而可生物降解系统无需手术取出，从而拓宽了治疗应用范围。微型化长效植入有助于提高慢性病患者的用药依从性，并为门诊治疗提供支援。此外，主要企业不断增加的研发投入、临床试验的进展以及新产品推出，都促进了植入式药物输送装置市场份额的扩大。

全球植入式药物输送装置市场主要受多种关键因素驱动，其中最主要的是慢性病病例的激增，包括心血管疾病、糖尿病和癌症。此外，对微创手术和治疗的需求不断增长，以及易患慢性病的老年人口显着增加，也显着推动了市场扩张。同时，全球对植入式装置技术进步的关注，例如可程式设计和可生物降解药物传输系统的设计，以及对可持续治疗方案日益增长的需求，也促进了植入式药物输送装置市场份额的扩大。此外，医疗保健产业降低成本的需求不断增长，以及便利的报销政策，也显着影响市场成长。因此，多个国家的政府目前正在实施相关政策，以促进医疗保健领域的先进技术发展，进而提振全球市场需求。此外，旨在开发创新植入式药物输送装置的研发活动的显着增加，也对市场动态产生了影响。其他重要因素包括人们对植入式药物输送装置益处的认识不断提高，以及对标靶药物输送和个人化医疗的高度重视，这些都极大地促进了植入式药物输送装置市场的成长。

由于慢性病高发生率以及对创新医疗解决方案的高度重视，美国是植入式药物输送装置的主要市场。例如，糖尿病、心臟病和癌症等慢性病是美国残疾和死亡的主要原因，每年造成4.5兆美元的国民医疗支出。此外，美国成熟的製药和医疗设备产业正在推动这些装置的研发和广泛应用。领先的研发倡议和有利的法规环境也为该市场的成长提供了支持。此外，对标靶治疗和个人化医疗日益增长的需求，以及对改善患者疗效的迫切需要，都促进了植入式药物输送装置在美国的普及，从而推动了市场扩张和创新。

植入式药物输送装置市场趋势：

将人工智慧 (AI) 和智慧感测器整合到个人化药物传输中

植入式药物传输装置的市场成长正因人工智慧（AI）的融合和智慧感测器技术的进步而改变。此外，研发投入正不断增加，用于先进感测器的微型化和无线供电技术。最新的智慧型帮浦配备了AI驱动的演算法，能够以每秒一次的间隔处理患者数据，从而实现即时剂量调整。云端连接支援远端医疗管理，使临床医生无需面对面会诊即可更改治疗通讯协定。研究表明，这些系统透过优化剂量控制，可将用药错误减少15%至25%。科学文献表明，具有自动交换机制的智慧型输液装置可显着提高给药的连续性和准确性。研究表明，自动促效剂交换系统可在无需人工评估的情况下维持稳定的治疗水准。此外，各公司正在推出各种穿戴式智慧健康感测器。 2024年，华为TruSense系统发布，为使用者提供精准、科学的健康和健身技术。

可生物降解和可生物吸收的材料为设备设计带来创新。

生物可降解材料正在从根本上改变植入式设备的设计，无需手术取出。科学家开发出可植入的生物可降解摩擦奈米发电机，可透过无线超音波活化产生电脉衝。这些设备透过电场输送抗有丝分裂药物，同时抑制癌细胞中的微管组装。治疗结束后，这些设备会完全降解，无需二次取出手术。美国国立卫生研究院 (NIH) 的 2025 DEBUT 挑战计画透过专案资助计画支持生物可降解植入的创新。材料方面的进步包括生物相容性聚合物，这些聚合物在治疗过程中保持结构完整性，并在治疗后安全溶解。研究人员正在探索丝素蛋白和生物可降解弹性体在压力感测器和药物储存中的应用。这些材料具有可控的降解特性，同时最大限度地减少异物反应。产学研合作已研发出硬币大小的生物感测器，其佩戴舒适度和精度均已提升。生物可降解能源采集电源无需手术更换电池。这项技术可用于术后恢復和急性期治疗的暂时植入。 2024年，全球医疗技术领导者史赛克公司宣布在印度推出InSpace，这是首款用于关节镜治疗大规模不可修復性肩迴旋肌断裂（MIRCT）*的球囊植入。 MIRCT是肩关节疾病的主要原因之一。 <sup>1,2,3</sup> InSpace为外科医生在肩关节治疗领域提供了新的选择，帮助他们更有效地满足患者的需求。

用于慢性疾病管理的微型长效植入

微型化技术使得火柴棒大小的植入能够持续释放药物六个月至一年。 Vivani Medical 的 GLP-1Exenatide植入在 LIBERATE-1 试验中迅速招募了 24 名受试者，仅花了四周时间。这种皮下植入装置旨在解决慢性病患者用药依从性差的问题，而这问题影响着 50% 的慢性疾病患者。植入能够维持稳定的药物浓度，避免注射带来的波动。此外，重量不足 45 克的紧凑型帮浦能够实现 0.05 毫升/小时的微量给药精度。最新装置采用磁感应充电技术，可在 10-20 毫米的组织深度内进行非侵入性能量传输。临床数据显示，六个月的植入能够提高患者的用药依从性，同时减少就诊次数。目前，该技术正着眼于将其应用于糖尿病和肥胖症的治疗，以实现每年一次的给药方案。这项技术对于难以进行日常药物管理的年长患者尤其有益。随着植入式药物输送装置的微型化技术使得门诊手术成为可能，从而降低了医疗成本，该领域的市场成长正在加速。企业报告称，与每日服药相比，患者更倾向于选择长效植入。

目录

第一章：序言

第二章：调查范围与调查方法

  • 调查目标
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 二手资讯
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章 引言

5. 全球植入式药物传输装置市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 按产品类型分類的市场区隔

  • 植入式药物释放型支架
  • 植入式避孕药物输送装置
  • 植入式眼内药物输送装置
  • 植入式近距离放射种子装置
  • 植入式药物输送帮浦装置

第七章 按技术分類的市场区隔

  • 可生物降解植入
  • 不可生物降解的植入

第八章 按应用分類的市场细分

  • 肿瘤学
  • 循环系统疾病
  • 自体免疫疾病
  • 妇产科
  • 其他的

第九章 依最终用户分類的市场细分

  • 医院
  • 门诊手术中心
  • 其他的

第十章 按地区分類的市场细分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十一章 驱动因素、限制因素与机会

第十二章 价值链分析

第十三章 波特五力分析

第十四章：定价分析

第十五章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Delpor Inc.
    • Koninklijke DSM NV
    • Medtronic plc
    • Theragenics Corporation
Product Code: SR112026A8302

The global implantable drug delivery devices market size was valued at USD 16.2 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 28.0 Billion by 2034, exhibiting a CAGR of 6.25% during 2026-2034. North America currently dominates the market, holding a significant market share of over 40.7% in 2025. The heightened usage of artificial intelligence (AI)-enabled smart sensors, biodegradable materials, and miniaturized long-acting implants is supporting the market growth. Additionally, real-time dosing algorithms and cloud connectivity improve accuracy and cut medication errors, while biodegradable systems eliminate removal surgeries and expand therapeutic applications. Miniaturized, long-duration implants enhance adherence in chronic disease management and support outpatient care. Furthermore, the growing research and development (R&D) investments, clinical trial progress, and new product launches from leading companies are expanding the implantable drug delivery devices market share.

The global implantable drug delivery devices market is principally bolstered by numerous critical factors, majorly encompassing the burgeoning cases of chronic conditions, which generally include cardiovascular issues, diabetes, or cancer. Besides this, the amplifying requirement for minimally invasive surgeries or procedures and the notable boost in geriatric population, which is comparatively more prone to chronic disorders, are significantly fueling market expansion. In addition to this, global focus on technological enhancements in implantable devices, like the designing of programmable or biodegradable drug delivery systems, and the accelerating need for prolonged therapeutic solutions are expanding the implantable drug delivery devices market share. Apart from this, the bolstering necessity to lower expenditure in healthcare landscape and the easy accessibility of profitable reimbursement regulations are impacting the market growth intensely. In line with this, governments of several countries are currently launching ventures to incentivize leading-edge technologies for healthcare, which, as a consequence, is heightening the market demand worldwide. Moreover, the significant elevation in research and development (R&D) efforts targeted at launching innovative and novel implantable drug delivery devices are also influencing market dynamics. Other pivotal factors, enveloping the magnifying consciousness associated with the advantages of utilizing implantable drug delivery devices along with the robust emphasis on targeted drug delivery as well as personalized medicine, are notably contributing to the implantable drug delivery devices market growth.

The United States is a prominent market for implantable drug delivery devices, driven by a high prevalence of chronic diseases and a strong focus on innovative healthcare solutions. For instance, according to the chronic diseases, including diabetes, heart conditions, and cancer, are the major causes of both disability and death across the U.S., accounting for USD 4.5 trillion annually in nation's health care expenditure. Moreover, the country's well-established pharmaceutical and medical device industries facilitate the development and adoption of these devices. Furthermore, advanced research and development initiatives, coupled with a favorable regulatory environment, support the growth of this market. Additionally, the increasing demand for targeted and personalized therapies, as well as the need for improved patient outcomes, contribute to the rising adoption of implantable drug delivery devices in the United States. This fuels market expansion and innovation.

Implantable Drug Delivery Devices Market Trends:

Integration Of Artificial Intelligence (AI) and Smart Sensors for Personalized Drug Delivery

The implantable drug delivery devices market growth is experiencing transformation through AI integration and smart sensor technologies. Moreover, there is an increase in research and development (R&D) investments for advanced sensor miniaturization and wireless power capabilities. Modern smart pumps incorporate AI-driven algorithms processing patient data at one-second intervals for real-time dosage adjustments. Cloud connectivity enables remote therapy management with clinicians modifying treatment protocols without physical consultations. Research demonstrates these systems reduce medication errors by 15-25% through optimized dosage control. Scientific publications confirm smart infusion devices with automated replacement mechanisms significantly enhance drug delivery continuity and accuracy. Studies showed automated vasoactive drug replacement systems maintaining consistent therapeutic levels while eliminating manual assessment requirements. Furthermore, companies are launching various smart health sensors in the form of wearables. In 2024, HUAWEI TruSense System was launched which provided accurate and science-based health and fitness technology to users.

Biodegradable And Bioresorbable Materials Revolutionizing Device Design

Biodegradable materials are fundamentally changing implantable device architectures eliminating surgical removal requirements. Scientists developed implantable biodegradable triboelectric nanogenerators generating electrical stimulation through wireless ultrasound activation. These devices deliver anti-mitotic drugs while disrupting cancer cell microtubule assembly through electrical fields. Complete device degradation occurs post-therapy without secondary extraction procedures. NIH's 2025 DEBUT Challenge supports biodegradable implant innovations through targeted funding programs. Material advances include biocompatible polymers maintaining structural integrity during therapy then safely dissolving. Research explores silk fibroin proteins and biodegradable elastomers for pressure sensors and drug reservoirs. These materials minimize foreign body reactions while providing controlled degradation profiles. Academic-industry collaborations delivered coin-sized biosensors with enhanced wearability and accuracy. Biodegradable power sources using energy harvesting eliminate battery replacement surgeries. The technology enables temporary therapeutic implants for post-surgical recovery or acute condition management. In 2024, Stryker, a worldwide leader in medical technology, declared the introduction of InSpace, the initial balloon implant designed for arthroscopic treatment of massive irreparable rotator cuff tears (MIRCTs)*, in India. MIRCTs are among the leading factors contributing to shoulder problems. 1,2,3 InSpace offers a fresh alternative for surgeons in the shoulder care continuum, helping them address their patients' needs more effectively.

Miniaturized Long-Acting Implants for Chronic Disease Management

Miniaturization technologies enable matchstick-sized implants delivering medications for six months to one year. Vivani Medical's GLP-1 exenatide implant achieved rapid LIBERATE-1 trial enrollment with 24 subjects recruited within four weeks. The subdermal device addresses medication non-adherence affecting 50% of chronic disease patients. The implant maintains consistent drug levels avoiding peaks and troughs associated with injections. Moreover, miniaturized pumps weighing under 45 grams deliver micro-doses at 0.05 mL/hour precision. Modern devices incorporate magnetic induction charging through 10 to 20mm tissue depth enabling non-invasive power transfer. Clinical evidence demonstrates six-month implants reducing hospital visits while improving adherence rates. Development focuses on once-yearly administration possibilities for diabetes and obesity management. The technology particularly benefits elderly patients struggling with daily medication regimens. Implantable drug delivery devices market growth accelerates as miniaturization enables outpatient procedures reducing healthcare costs. Companies report a higher percentage of patient preference for long-acting implants over daily medications.

Implantable Drug Delivery Devices Industry Segmentation:

Analysis by Product Type:

  • Implantable Drug Eluting Stents
  • Implantable Contraceptive Drug Delivery Devices
  • Implantable Intraocular Drug Delivery Devices
  • Implantable Brachytherapy Seeds Devices
  • Implantable Drug Delivery Pump Devices

Implantable drug eluting stents lead the market with around 32.2% of market share in 2025, driven by their role in preventing restenosis in coronary arteries. These devices are designed to release drugs directly at the site of arterial blockages, reducing the risk of re-narrowing after stent implantation. The integration of drug-eluting technology with stents enhances the efficacy of cardiovascular treatments, addressing critical challenges in managing coronary artery disease. The growing prevalence of heart-related conditions, coupled with advancements in stent design and drug formulations, is fueling market growth. Additionally, the shift toward minimally invasive procedures and the increasing preference for DES over bare-metal stents, due to their reduced risk of complications, further supports market expansion. As the demand for more effective treatments rises, implantable drug-eluting stents continue to dominate as a leading choice in the cardiovascular sector.

Analysis by Technology:

  • Biodegradable Implants
  • Non-Biodegradable Implants

Non-biodegradable leads the market in 2025. These devices are designed to release therapeutics over extended periods, offering controlled and sustained release without the need for frequent re-administration. Non-biodegradable systems, often used in the treatment of chronic conditions such as diabetes, cancer, and pain management, are durable and provide long-term therapeutic benefits. These devices typically include materials like metals, polymers, or ceramics, which ensure stability and longevity in the human body. Additionally, the demand for non-biodegradable drug delivery systems is driven by their ability to maintain consistent drug levels, improving patient compliance and reducing the need for repeated interventions. With advancements in materials science and device engineering, the market for non-biodegradable systems is expected to grow, offering significant potential for pharmaceutical companies seeking to enhance therapeutic delivery while minimizing side effects.

Analysis by Application:

  • Oncology
  • Cardiovascular
  • Autoimmune Diseases
  • Obstetrics and Gynecology
  • Others

Cardiovascular leads the market in 2025 by application, driven by the widespread occurrence of heart-related conditions and the growing need for advanced and effective treatment options. Devices used in cardiovascular applications, such as drug-eluting stents and pacemakers, play a crucial role in managing conditions like coronary artery disease, arrhythmias, and heart failure. The growing aging population, coupled with unhealthy lifestyle habits, has contributed to an increase in cardiovascular diseases, driving demand for innovative therapeutic solutions. Implantable drug delivery systems in this category enable precise medication release, which enhances treatment effectiveness, minimizes potential complications, and contributes to better patient outcomes. Furthermore, technological advancements in the design and material properties of cardiovascular devices are contributing to the growth of this segment. As healthcare systems focus on improving heart disease management, cardiovascular applications will remain at the forefront of market development.

Analysis by End User:

  • Hospitals
  • Ambulatory Surgery Centers
  • Others

Hospitals lead the market in 2025, accounting for a significant share due to their central role in patient treatment and care. Hospitals are primary settings for the implantation of drug delivery systems, particularly for patients requiring specialized procedures like stent placement or pain management devices. These institutions benefit from the latest innovations in implantable devices, offering targeted therapies for chronic conditions such as diabetes, cancer, and cardiovascular diseases. Additionally, hospitals are equipped with advanced medical technologies and skilled professionals necessary for the successful administration and monitoring of these devices. With the ongoing enhancement of healthcare infrastructure worldwide, hospitals continue to serve as the primary users of implantable drug delivery systems. Furthermore, their ability to integrate new technologies into routine care, combined with rising patient volumes and the increasing complexity of treatments, ensures that hospitals will continue to dominate the market share in the years to come and will contribute to a positive implantable drug delivery devices market outlook.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 40.7%. This region is chiefly influenced by highly robust healthcare ecosystem, substantial efforts and investments pertaining to research and development programs, and elevated requirement for cutting-edge treatment methodologies. The region heavily profits from resilient regulatory aid, facilitating quick utilization leading-edge technologies. In addition to this, the establishment of leading pharmaceutical firms and device producers in Canada as well as the United States further prompts significant growth in this market, with an active emphasis on enhancing patient outcomes by leveraging targeted therapies. Besides this, the magnification of chronic diseases prevalence, for instance cancer, diabetes, or cardiovascular disorders, is escalating requirement for implantable drug delivery methods. For instance, as per industry reports, in 2024, around 70% of individuals in Canada were suffering from type 2 diabetes, while 90% of individuals were suffering from type 1 diabetes. Furthermore, North America's well-structured reimbursement policy framework and boosting awareness regarding the profits of implantable systems also strengthens its domination in the global industry, prompting constant innovations in this segment.

Key Regional Takeaways:

United States Implantable Drug Delivery Devices Market Analysis

The United States drives global innovation through FDA's progressive regulatory approach balancing safety with timely market access. Orchestra BioMed received IDE approval in 2025 initiating a 740-patient pivotal trial for Virtue SAB. The sirolimus-angioinfusion balloon addresses coronary restenosis affecting 325,000 patients annually. FDA breakthrough designations expedite development timelines for devices addressing unmet medical needs. Government healthcare programs including Medicare provide coverage for approved implantable devices supporting market growth. Academic medical centers conduct pioneering research advancing drug delivery technologies through federal grants. The country hosts headquarters of major device manufacturers investing billions in R&D annually. Clinical trial infrastructure supports rapid patient enrollment accelerating product development cycles. Specialized manufacturing facilities produce implantable devices meeting stringent quality requirements. Healthcare provider training programs ensure proper device implantation and patient management protocols.

Europe Implantable Drug Delivery Devices Market Analysis

European markets demonstrate strong adoption driven by universal healthcare systems prioritizing cost-effective chronic disease management. Strategic partnerships between pharmaceutical and device companies accelerate innovation in drug-device combinations. Government initiatives promote digital health transformation integrating smart implantable devices into care pathways. Nordic countries lead adoption rates with comprehensive reimbursement covering advanced drug delivery systems. Research consortiums combining academic and industry partners receive EU funding for collaborative projects. Regulatory harmonization across member states simplifies multi-country clinical trials and market launches. Patient advocacy groups influence policy decisions supporting access to innovative implantable therapies. In 2025, Roche announced that it has obtained the EU CE mark for its Port Delivery Platform with Susvimo, to be marketed in the EU as Contivue(R). The system consists of the implantable device through which Susvimo is administered, and four supportive devices used to initially fill, insert, refill, and remove the implant (if needed). Susvimo(R) (ranibizumab injection) 100 mg/mL for intravitreal use via the Susvimo eye implant is currently under review with the European Medicines Agency (EMA) for the treatment of nAMD. With immediate and predictable durability, Contivue with Susvimo provides continuous delivery of a customized formulation of ranibizumab directly to the eye.

Asia Pacific Implantable Drug Delivery Devices Market Analysis

Asia Pacific emerges as the fastest-growing region driven by massive diabetic populations requiring advanced management solutions. China's diabetes market is projected to attain USD 9.81 Billion by 2033 according to the predictions of IMARC Group. Government healthcare reforms expand insurance coverage for implantable devices improving patient access. Joint ventures between international and local companies facilitate technology transfer and market entry. The rise in disposable income among Indians also drives the demand for premium healthcare including advanced drug delivery options. Japan's aging population creates opportunities for implantable devices managing multiple chronic conditions simultaneously. Manufacturing capabilities in the region reduce production costs making devices more affordable. Regulatory authorities streamline approval processes attracting clinical trials and product launches. Hospital infrastructure investments support adoption of sophisticated implantable technologies requiring specialized facilities. Digital health initiatives integrate implantable devices with telemedicine platforms enabling remote monitoring.

Latin America Implantable Drug Delivery Devices Market Analysis

Latin America demonstrates increasing adoption driven by public health initiatives addressing chronic disease burdens. Brazilian research institutions partner with European companies advancing flow chemistry for device manufacturing. Local production capabilities reduce import dependencies making implantable devices more accessible. Government programs in Mexico and Colombia expand healthcare coverage including advanced medical devices. Private healthcare sectors in major cities adopt latest implantable technologies attracting medical tourism. Regulatory harmonization initiatives facilitate multi-country product registrations reducing market entry barriers. Academic institutions develop local expertise through international collaborations and training programs. Infrastructure improvements support distribution networks ensuring device availability in remote areas. Economic growth enables middle-class expansion increasing demand for quality healthcare including implantable solutions.

Middle East and Africa Implantable Drug Delivery Devices Market Analysis

Middle East markets advance through government visions prioritizing healthcare sector development and medical device manufacturing. Saudi Aramco's collaboration developing modular flow reactors demonstrates commitment to advanced technology adoption. Gulf countries invest heavily in healthcare infrastructure including specialized centers for device implantation. African markets show potential with South Africa leading adoption of implantable technologies through private healthcare. International partnerships bring expertise and investment supporting local capacity building initiatives. Medical training programs develop skilled healthcare professionals capable of managing complex implantable devices. Regulatory frameworks evolve to balance patient access with safety requirements for new technologies. Disease burden from diabetes and cardiovascular conditions drives demand for long-term therapeutic solutions.

Competitive Landscape:

The global implantable drug delivery devices market is highly competitive, with numerous key players focusing on technological advancements, strategic partnerships, and product innovation to enhance market position. For instance, in October 2024, Silo Pharma, Inc., a biopharmaceutical firm focused on designing drug delivery systems, announced positive results for its recent dissolution and sterilization tests of its new implant SP-26 ketamine-loaded, developed for fibromyalgia and chronic pain. These tests were carried out as per the development agreement with Sever Pharma Solutions. As these conditions become more widespread, the necessity for efficient and enduring treatment options is steadily increasing. Additionally, the market is influenced by increasing regulatory requirements, with manufacturers striving to meet stringent safety and quality standards. Competition is also shaped by pricing strategies, market penetration, and the ability to secure partnerships with healthcare providers and pharmaceutical companies to expand distribution channels globally.

The report provides a comprehensive analysis of the competitive landscape in the implantable drug delivery devices market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Boston Scientific Corporation
  • Delpor Inc.
  • Koninklijke DSM N.V.
  • Medtronic plc
  • Theragenics Corporation

Key Questions Answered in This Report

  • 1.How big is the implantable drug delivery devices market?
  • 2.What is the future outlook of implantable drug delivery devices market?
  • 3.What are the key factors driving the implantable drug delivery devices market?
  • 4.Which region accounts for the largest implantable drug delivery devices market share?
  • 5.Which are the leading companies in the global implantable drug delivery devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Implantable Drug Delivery Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Implantable Drug Eluting Stents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Implantable Contraceptive Drug Delivery Devices
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Implantable Intraocular Drug Delivery Devices
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Implantable Brachytherapy Seeds Devices
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Implantable Drug Delivery Pump Devices
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Biodegradable Implants
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Non-Biodegradable Implants
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Autoimmune Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Obstetrics and Gynecology
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Ambulatory Surgery Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Boston Scientific Corporation
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Delpor Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Koninklijke DSM N.V.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Medtronic plc
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Theragenics Corporation
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio

List of Figures

  • Figure 1: Global: Implantable Drug Delivery Devices Market: Major Drivers and Challenges
  • Figure 2: Global: Implantable Drug Delivery Devices Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Implantable Drug Delivery Devices Market: Breakup by Product Type (in %), 2025
  • Figure 5: Global: Implantable Drug Delivery Devices Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Implantable Drug Delivery Devices Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Implantable Drug Delivery Devices Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Implantable Drug Delivery Devices Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Implantable Drug Delivery Devices (Implantable Drug Eluting Stents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Implantable Drug Delivery Devices (Implantable Drug Eluting Stents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Implantable Drug Delivery Devices (Implantable Contraceptive Drug Delivery Devices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Implantable Drug Delivery Devices (Implantable Contraceptive Drug Delivery Devices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Implantable Drug Delivery Devices (Implantable Intraocular Drug Delivery Devices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Implantable Drug Delivery Devices (Implantable Intraocular Drug Delivery Devices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Implantable Drug Delivery Devices (Implantable Brachytherapy Seeds Devices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Implantable Drug Delivery Devices (Implantable Brachytherapy Seeds Devices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Implantable Drug Delivery Devices (Implantable Drug Delivery Pump Devices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Implantable Drug Delivery Devices (Implantable Drug Delivery Pump Devices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Implantable Drug Delivery Devices (Biodegradable Implants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Implantable Drug Delivery Devices (Biodegradable Implants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Implantable Drug Delivery Devices (Non-Biodegradable Implants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Implantable Drug Delivery Devices (Non-Biodegradable Implants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Implantable Drug Delivery Devices (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Implantable Drug Delivery Devices (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Implantable Drug Delivery Devices (Cardiovascular) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Implantable Drug Delivery Devices (Cardiovascular) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Implantable Drug Delivery Devices (Autoimmune Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Implantable Drug Delivery Devices (Autoimmune Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Implantable Drug Delivery Devices (Obstetrics and Gynecology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Implantable Drug Delivery Devices (Obstetrics and Gynecology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Implantable Drug Delivery Devices (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Implantable Drug Delivery Devices (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Implantable Drug Delivery Devices (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Implantable Drug Delivery Devices (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Implantable Drug Delivery Devices (Ambulatory Surgery Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Implantable Drug Delivery Devices (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Implantable Drug Delivery Devices (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Implantable Drug Delivery Devices (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: North America: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: North America: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: United States: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: United States: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Canada: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Canada: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Asia-Pacific: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Asia-Pacific: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: China: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: China: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Japan: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Japan: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: India: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: India: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: South Korea: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: South Korea: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Australia: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Australia: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Indonesia: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Indonesia: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Others: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Others: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Europe: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Europe: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Germany: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Germany: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: France: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: France: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: United Kingdom: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: United Kingdom: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Italy: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Italy: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Spain: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Spain: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Russia: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Russia: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Latin America: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Latin America: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Brazil: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Brazil: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Mexico: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Mexico: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Others: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Others: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Middle East and Africa: Implantable Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Middle East and Africa: Implantable Drug Delivery Devices Market: Breakup by Country (in %), 2025
  • Figure 87: Middle East and Africa: Implantable Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Global: Implantable Drug Delivery Devices Industry: Drivers, Restraints, and Opportunities
  • Figure 89: Global: Implantable Drug Delivery Devices Industry: Value Chain Analysis
  • Figure 90: Global: Implantable Drug Delivery Devices Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Implantable Drug Delivery Devices Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Implantable Drug Delivery Devices Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 3: Global: Implantable Drug Delivery Devices Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: Implantable Drug Delivery Devices Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Implantable Drug Delivery Devices Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Implantable Drug Delivery Devices Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Implantable Drug Delivery Devices Market: Competitive Structure
  • Table 8: Global: Implantable Drug Delivery Devices Market: Key Players